Ayurvedic pharmaceutics (Bhaishajya Kalpana) codifies dosage forms with explicit preparation rules for solvent choice, process intensity, and matrix design principles that closely parallel modern drug delivery science. The objectives of study that maps classical Ayurvedic dosage forms to modern drug delivery analogues, specifies quality control (QC) and Chemistry, Manufacturing and Controls (CMC) expectations (including stability and release testing) and summarizes controlled clinical evidence and a translational roadmap for development. Methodology of narrative review of authoritative primers (AFI/API), pharmaceutics/QC resources (HPTLC/HPLC/ICP-MS/XRD/TEM), WHO herbal QC guidance, and controlled trials in osteoarthritis and rheumatoid arthritis. Sneha kalpana (medicated lipids) aligns with Lipid based drug delivery systems (LBDDS) and demands oxidation microstructure metrics; Bhasma parallels engineered micro/nano particulates requiring XRD/TEM/ICP-MS; Asava-arishta operate as hydro alcoholic extraction/permeation systems; Avaleha/Vati behave as matrix and sustained release platforms. Robust QC uses orthogonal analytics (HPTLC/HPLC/GC-MS, ICP-MS, XRD/TEM, microbes/aflatoxins/pesticides), with GMP under Schedule T and pharmacopeial anchors (AFI/API). Controlled trials show excellent safety and modest, clinically meaningful efficacy; one multicentre Osteoarthritis (OA) study demonstrated equivalence to celecoxib or glucosamine, supporting equivalence non-inferiority designs. Ayurvedic dosage forms are intentional formulation technologies that can be evaluated with contemporary drug delivery rigor through Quality Target Product Profiles (QTPPs) and Chemistry, Manufacturing and Controls (CMCs) stability and release testing, and clinically aligned specifications.
Keywords: Ayurveda dosage forms, drug delivery, HPTLC/HPLC, ICP-MS, XRD/TEM, Schedule T GMP.
How to cite this article: Pardeshi P, Nangare N, Khobragade S, Deshmukh A. Classics to clinics: mapping Ayurveda dosage forms to modern drug delivery systems. Int J Drug Deliv Technol. 2026;16(4s): 332-337; DOI: 10.25258/ijddt.16.4s.39
Source of support: Nil.
Conflict of interest: None